These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32535895)

  • 1. Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.
    Zhou Y; Krebs K; Milani L; Lauschke VM
    Clin Pharmacol Ther; 2021 Jan; 109(1):160-174. PubMed ID: 32535895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of hypersensitivity drug reactions.
    Negrini S; Becquemont L
    Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
    Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
    Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic information derived from analysis of HLA alleles.
    Gatanaga H; Honda H; Oka S
    Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
    Negrini S; Becquemont L
    Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis.
    Manson LEN; van den Hout WB; Guchelaar HJ
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.
    Daly AK
    Curr Drug Metab; 2014 Feb; 15(2):196-201. PubMed ID: 24694233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on HLA alleles associated with adverse drug reactions.
    Fricke-Galindo I; LLerena A; López-López M
    Drug Metab Pers Ther; 2017 May; 32(2):73-87. PubMed ID: 28315856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East.
    Masmoudi HC; Afify N; Alnaqbi H; Alhalwachi Z; Tay GK; Alsafar H
    Pharmacogenomics; 2022 Aug; 23(12):695-708. PubMed ID: 35971864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
    Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
    Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
    Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
    Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.
    Bharadwaj M; Illing P; Theodossis A; Purcell AW; Rossjohn J; McCluskey J
    Annu Rev Pharmacol Toxicol; 2012; 52():401-31. PubMed ID: 22017685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
    Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
    Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
    Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
    Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.
    Zhou Y; Lauschke VM
    Hum Genet; 2022 Jun; 141(6):1113-1136. PubMed ID: 34652573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions].
    Xiong Y; Zhang W; Chen X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):749-57. PubMed ID: 25080918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.